--- title: "OMNIAB INC C/WTS (TO PUR COM) | 8-K: FY2025 Revenue: USD 18.67 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/277833498.md" datetime: "2026-03-04T21:15:31.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/277833498.md) - [en](https://longbridge.com/en/news/277833498.md) - [zh-HK](https://longbridge.com/zh-HK/news/277833498.md) generator: "portal-rs" --- # OMNIAB INC C/WTS (TO PUR COM) | 8-K: FY2025 Revenue: USD 18.67 M Revenue: As of FY2025, the actual value is USD 18.67 M. EPS: As of FY2025, the actual value is USD -0.57. EBIT: As of FY2025, the actual value is USD -71.63 M. ### Fourth Quarter 2025 Financial Results #### Segment Revenue - Total revenue was $8.4 million, compared with $10.8 million for the same period in 2024, primarily due to a decline in license and service revenue, partially offset by an increase in milestone and royalty revenue and the addition of xPloration revenue. - License and milestone revenue was $5,892 thousand, down from $8,650 thousand in Q4 2024. - Service revenue was $2,236 thousand, down from $2,533 thousand in Q4 2024. - xPloration revenue was $30 thousand, up from $0 in Q4 2024. - Royalty revenue was $218 thousand, compared to -$379 thousand in Q4 2024. #### Operational Metrics - Research and Development Expense was $13.9 million, compared with $13.3 million for Q4 2024, due to a $3.9 million impairment charge related to certain small molecule ion channel property and equipment, partially offset by lower personnel and external expenses. - General and Administrative Expense was $6.8 million, compared with $7.4 million for Q4 2024, primarily due to lower share-based compensation expense. - Loss from Operations was -$15,766 thousand, compared to -$15,880 thousand for Q4 2024. - Net Loss was -$14.2 million, compared with a net loss of -$13.1 million for Q4 2024. ### Full Year 2025 Financial Results #### Segment Revenue - Total revenue for 2025 was $18.7 million, compared with $26.4 million for 2024, primarily due to decreases in license and milestone revenue and a decline in service revenue, partially offset by an additional $0.8 million in xPloration revenue. - License and milestone revenue was $9,771 thousand, down from $13,866 thousand in 2024. - Service revenue was $7,263 thousand, down from $11,949 thousand in 2024. - xPloration revenue was $754 thousand, up from $0 in 2024. - Royalty revenue was $878 thousand, up from $576 thousand in 2024. #### Operational Metrics - Cost of xPloration Revenue was $0.3 million for 2025, consisting of direct costs associated with the sale of the xPloration instrument and consumables. - Research and Development Expense was $47.8 million, compared with $55.1 million for 2024, primarily due to lower personnel and external expenses, reduced share-based compensation, and a decline in contract research costs, partially offset by a $3.9 million impairment charge. - General and Administrative Expense was $29.2 million, compared with $30.7 million for 2024, primarily due to lower legal fees and share-based compensation expense. - Other Operating Income, Net was $2.5 million for 2025, reflecting a $3.0 million gain from the sale of a small molecule Kv7.2 program, partially offset by a $0.3 million increase in contingent liability expense. - Loss from Operations was -$68,969 thousand, compared to -$74,502 thousand for 2024. - Net Loss was -$64.8 million, compared with a net loss of -$62.0 million for 2024. #### Cash Flow - As of December 31, 2025, OmniAb had cash, cash equivalents and short-term investments totaling $54.0 million. - Cash and cash equivalents were $25,524 thousand, down from $27,598 thousand in 2024. - Short-term investments were $28,501 thousand, down from $31,836 thousand in 2024. #### Unique Metrics - As of December 31, 2025, OmniAb had 107 active partners and 407 active programs, including 32 OmniAb-derived programs in clinical development or commercialization. - The company launched OmniUltra™ in December 2025, a transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, which also enables the isolation of picobodies™. ### 2026 Financial Guidance OmniAb expects 2026 revenue to be between $25 million and $30 million. Costs and operating expenses are projected to range from $80 million to $85 million. The company anticipates ending 2026 with cash and cash equivalents in the range of $30 million to $35 million, and projects an effective tax rate of approximately 0%. ### Related Stocks - [OABIW.US](https://longbridge.com/en/quote/OABIW.US.md) ## Related News & Research - [US listing could put Japan's Kioxia in global AI spotlight, Voya's Thomas says](https://longbridge.com/en/news/298696734.md) - [Oil prices set to end week over $100 for first time in nearly 4 months](https://longbridge.com/en/news/298661520.md) - [Stellantis CEO highlights diverging US and global strategies](https://longbridge.com/en/news/298636085.md) - [Huang rejects 'circular financing' label for NVIDIA's AI bets](https://longbridge.com/en/news/298649945.md) - [Last Minute Thought: Buy or Sell Oracle Stock as Earnings Loom? Here’s What Scotiabank Thinks](https://longbridge.com/en/news/298627363.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**